POST Online Media Lite Edition


Valeant announces planned management departure

Staff writer |
Laval, QC, Canada - June 16, 2014, Laval, QC, Canada - Valeant Pharmaceuticals International announced that Ryan Weldon, the group chairman, will be leaving the company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestle.

Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma.

Mr. Weldon was appointed as Executive Vice President/Company Group Chairman Valeant Pharmaceuticals International, Inc. in December 2012. He has served as Vice President & General Manager, Aesthetics since December 2011 and Vice President & General Manager, Neurology & Other since January 2010. He joined Valeant in 2008 after working for McKinsey & Co. and Johnson & Johnson.


Pershimex Resources appoints Serge M. Racine to board
DAVIDsTEA appoints Frank Zitella as chief financial officer
DAVIDsTEA apoints two to board
CN appoints Jean-Jacques Ruest as president, CEO and director
Acasti Pharma appoints Donald Olds to board

What to read next

Valeant appoints Howard Schiller to board of directors
Valeant appoints Philip W. Loberg as interim CFO
Valeant to appoint Robert L. Rosiello as CFO